The lack of treatments for menopause forces hospitals to pay three times more and some patients up to 20 times more

The shortage of hormonal treatments for menopause has led many women in Spain to search pharmacies for alternatives. The issue began in May, with Catalonia becoming a focal point for the crisis. While magistral formulations were initially considered a solution, the focus has shifted to the costly importation of medications from other European countries. This has resulted in increased costs for patients, as many are forced to turn to more expensive, non-funded alternatives. The situation is exacerbated by high demand across Europe, limiting the availability of treatments like Lenzetto. The Spanish health authorities are working with European counterparts to address the supply issues, but full normalization is not expected until 2027.